Atopic Dermatitis in Children

Lacey L. Kruse*, Anthony J Mancini

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Atopic dermatitis (AD) is extremely common in the pediatric population, and most children with AD will first present to their primary care provider (PCP). The PCP can recognize AD by its clinical features, including itch, a chronic relapsing course, and the characteristic eruption. The cornerstone of AD therapy is dry skin care, typically a short daily bath/shower followed by an emollient applied to all skin. Most children with AD will also require topical medications, such as topical corticosteroids and/or topical nonsteroidal therapies. For children with more severe disease, systemic agents, including several novel therapies, may be required. In managing AD, the clinician must monitor for side effects of medications as well as complications of the AD itself, the most common of which is secondary infection. An understanding of the pathogenesis, treatments, and complications of AD is essential for the PCP, as untreated (or undertreated) AD has a significant impact on the quality of life of affected children and their caregivers.

Original languageEnglish (US)
Pages (from-to)e121-e128
JournalPediatric annals
Volume53
Issue number4
DOIs
StatePublished - Apr 2024

Funding

Lacey L. Kruse discloses research grants received from Sanofi-Aventis US LLC, Eli Lilly and Company LLC, and LEO Pharma A/S. Anthony J. Mancini discloses serving as a paid consultant and/or advisor to Arcutis, Castle Creek, Dermavant, Galderma, ParaPRO, Sanofi-Regeneron, and Verrica.

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint

Dive into the research topics of 'Atopic Dermatitis in Children'. Together they form a unique fingerprint.

Cite this